Nevertheless, the failure of a large phase III clinical trial with Epacadostat in melanoma patients indicates that IDO, at least in this type of cancer, is not a suitable target to improve the efficacy of drugs such as Pembrolizumab. Here, IDO1 is linked to melanoma.